A Randomized, Blinded, Phase 2 Dose-Ranging Study of BMS-936558 (MDX-1106) in Subjects With Progressive Advanced/Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy

Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2011
This article has no abstract
Epistemonikos ID: a1912b051c27fe5ef83688edc65579d651b5a6ce
First added on: Jan 22, 2025